A Phase 1B/2 Open-Label, Ascending Single and Repeat Dose Clinical Trial Designed to Evaluate the Safety of Light-activated AU-011 for the Treatment of Subjects With Small to Medium Primary Choroidal Melanoma

Trial Profile

A Phase 1B/2 Open-Label, Ascending Single and Repeat Dose Clinical Trial Designed to Evaluate the Safety of Light-activated AU-011 for the Treatment of Subjects With Small to Medium Primary Choroidal Melanoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs AU 011 (Primary)
  • Indications Uveal melanoma
  • Focus Adverse reactions
  • Sponsors Aura Biosciences
  • Most Recent Events

    • 11 Nov 2017 Interim safety results published in an Aura Biosciences media release.
    • 25 Oct 2017 According to an Aura Bioscience media release, data from phase Ib part will be presented during a late-breaking session at the American Academy of Ophthalmology (AAO) Annual Meeting 2017.
    • 14 Sep 2017 Protocol was amended to change in the treatment arm from 2 to 5 and change in primary endpoint.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top